All In Biotech

Drug Trial Radar · NCT05179876

A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option

A Prospective, Open-label, Platform Study for Long-term Follow-up of Participants Using Study Intervention in Pulmonary Hypertension Parent Studies

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

280

Planned (sponsor's estimate)

Start

May 4, 2022

Primary completion

Jan 31, 2027

Study completion Sep 28, 2033

Sponsor

Lead sponsor
ActelionJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jan 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to enable participants with pulmonary hypertension (PH) currently treated with study intervention(s) in a clinical study (parent studies \[NCT03422328, NCT03904693,NCT04565990, NCT02932410, NCT03492177, and NCT04175600\]), to continue to benefit from the intervention after closure of the parent study in case they have no alternative means of access to the study intervention. This study will allow assessment of the long-term safety of each study intervention.

Conditions

  • Hypertension, Pulmonary

Interventions

  • MacitentanDrug

    Adult participants will receive oral dose of macitentan 10 milligrams (mg) tablet once daily. Children greater than or equal to (\>=) 2 year to less than (\<) 18 years will be given an oral macitentan dose tailored to their body weight, ensuring an equivalent level of systemic exposure as in adults.

  • SelexipagDrug

    Adult Participant will receive oral dose of selexipag tablet twice daily at the dose strength corresponding to their maintenance dose at the end of their parent study. Available strengths: 200, 400, 600, 800, 1000, 1200, 1400 and 1600 micrograms (µg). Children with body weight category of \>=50 kg will use the tablets at the required dose strength as described for adults. Children with a body weight \< 50 kg will receive tablets for pediatric use (dose strengths: 100 and 150 mcg), twice daily to enable continuation of individually maximum tolerated dose of selexipag according to their body weight category.

  • Macitentan/Tadalafil FDCDrug

    Participants will receive oral FDC of macitentan 10 mg and tadalafil 40 mg once daily during the course of the study as already received in the parent studies.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Treatment Emergent Adverse Events (TEAEs)Time frame: Baseline until End of Study (EOS) (up to 84 months)
  2. Frequency of TEAEs Leading to DiscontinuationTime frame: Baseline until EOS (up to 84 months)
  3. Frequency of Serious Adverse Events (SAEs)Time frame: Baseline until EOS (up to 84 months)
  4. Frequency of DeathsTime frame: Baseline until EOS (up to 84 months)

Locations

45 sites in 13 countries. Site status is shown where the registry gives one.

  • The Republican Scientific-Practical Center ''Cardiology''

    Minsk, Belarus · Recruiting

  • Minsk Regional Clinical Hospital Of The Red Banner Of Labor

    Minsk, Belarus · Completed

  • UZ Leuven

    Leuven, Belgium · Completed

  • University Multiprofile Hospital for Active Treatment- UMHAT Sveta Anna AD

    Sofia, Bulgaria · Recruiting

  • Beijing Anzhen Hospital 1

    Beijing, China · Recruiting

  • Beijing Anzhen Hospital

    Beijing, China · Recruiting

  • The Second Xiangya Hospital of Central South Hospital

    Changsha, China · Recruiting

  • Jiangsu Province Hospital

    Nanjing, China · Recruiting

  • Qingdao Women and Children's Hospital

    Qingdao, China · Recruiting

  • Childrens Hospital of Shanghai

    Shanghai, China · Recruiting

  • The First Affiliated Hospital of Xian Jiaotong University

    Xi'an, China · Recruiting

  • Gottsegen György Országos Kardiológiai Intézet

    Budapest, Hungary · Recruiting

  • Klinika Kardiologii Z Oddzialem Intensywnego Nadzoru Kardiologicznego UM W Bialymstoku

    Bialystok, Poland · Recruiting

  • Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy, Klinika Kardiologii

    Bydgoszcz, Poland · Completed

  • SPSK nr 7 SUM w Katowicach Gornoslaskie Centrum Medyczne im Prof Leszka Gieca

    Katowice, Poland · Recruiting

  • Oddzial Kardiologii Wojewodzki Szpital Specjalistyczny im W Bieganskiego

    Lodz, Poland · Completed

  • Wojewodzki Szpital Specjalistyczny im Stefana Kardynala Wyszynskiego SPZOZ

    Lublin, Poland · Completed

  • SPSK2 PUM Klinika Kardiologii

    Szczecin, Poland · Completed

  • Wojewodzki Szpital Specjalist Osrodek Badawczo Rozwojowy

    Wroclaw, Poland · Completed

  • Wojewodzki Szpital Specjalistyczny we Wroclawiu

    Wroclaw, Poland · Recruiting

  • Scientific and Research Institution of Cardiovascular Diseases Complex Problems

    Kemerovo, Russia · Completed

  • E.Meshalkin National Medical Research Center of the Ministry of Health of the Russian Federation

    Novosibirsk, Russia · Recruiting

  • Federal State Budgetary Institution

    Saint Petersburg, Russia · Completed

  • Institute of Cardiology of Tomsk National Research Medical Center of Rus Academy of Sciences

    Tomsk, Russia · Completed

  • Regional Clinical Hospital No1

    Tyumen, Russia · Recruiting

  • Abdullah, IA

    Durban, South Africa · Completed

  • Dr Kalla

    Lenasia, South Africa · Recruiting

  • Chungnam National University Hospital

    Daejeon, South Korea · Recruiting

  • Gachon University Gil Medical Center

    Incheon, South Korea · Recruiting

  • Seoul National University Hospital 1

    Seoul, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • The Catholic University of Korea Seoul St Marys Hospital

    Seoul, South Korea · Completed

  • Kaohsiung Veterans General Hospital

    Kaohsiung City, Taiwan · Recruiting

  • National Cheng Kung University Hospital

    Tainan, Taiwan · Recruiting

  • National Taiwan University Hospital

    Taipei, Taiwan · Recruiting

  • Taipei Veterans General Hospital

    Taipei, Taiwan · Recruiting

  • Chang-Gung Memorial Hospital, LinKou Branch

    Taoyuan, Taiwan · Recruiting

  • Maharaj Nakorn Chiang Mai hospital Faculty of Medicine

    Chiang Mai, Thailand · Recruiting

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.